EMA (EU)
EVENT
EMA workshop on the challenges in drug development, regulation and clinical practice in immune thrombocytopenia
Published: 6/30/2026Detected: 6/29/2026
Summary preview
This EMA workshop convenes multi-stakeholder input to update the EMA “Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia,” with particular…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountimmunology
hematology
pediatrics
clinical
safety
labeling
#immune thrombocytopenia
#chronic primary immune thrombocytopenia
#clinical development
#clinical trial endpoints
#study design
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026